MarginsXMarginsX
Home › Markets › Health Care › ORKA

Oruka Therapeutics Inc. (ORKA)

ORKA trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$99.24
-5.80% on the day
Market cap
$6.7B
Mid cap
Revenue · 2023
$0
Prior year not contiguous
Net income · 2023
-$5.3M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/907654/000095017024009809/0000950170-24-009809-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.

Profile

FieldValue
TickerORKA on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000907654
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2023

LineValue
Revenue$0
Net income-$5.3M
Operating income-$7.3M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$37.4M
Total assets$37.9M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
18.6 months
$191.5M cash at September 30, 2026
Share count, 1 year
+40.1%
2025-10-31 to 2026-10-31 · +5547.9% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$333.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$191.5M cash; operating cash flow -$30.9M a quarter.Report 2026-09-30
Shares outstanding67,822,359 (2026-10-31); 48,409,232 a year earlier; 14,410,143 three years earlier. 3y figure adjusted for splits (1-for-12 overall).Cover page 2026-10-31
Reverse splits, 3 years1; latest 1-for-12 on 2024-09-03Source 2024-09-03
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the marketLatest 2026-08-28
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $333.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$50.0M-$44.3M$191.5MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$41.2M-$33.1M$268.5MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2026
2026-03-31
Not filed-$31.8M-$23.6M$49.5MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
Not filed-$29.6M-$22.6M$46.9MNo debt tagsNeeds four quarters10-K 2026-03-12
Q3 2025
2025-09-30
Not filed-$30.3M-$21.6M$91.3MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2025
2025-06-30
Not filed-$24.6M-$23.1M$65.4MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2025
2025-03-31
Not filed-$21.0M-$20.9M$83.6MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q3 2024
2024-09-30
Not filed-$28.6MNot filed$410.9MNo debt tagsNeeds four quarters10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B52026-08-28
Latest annual report
ANNUAL REPORT
10-K2026-03-12
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-09
Latest current report
CURRENT REPORT
8-K2026-10-26
Latest proxy
PROXY STATEMENT
DEFA14A2026-04-17

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.4%
1 month+34.7%
3 months-2.6%
Year to date+247.6%
1 year+299.4%
From 52-week high-6.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
LNTHLantheus Holdings Inc.$101.72+0.13%$6.7B
NEOGNeogen Corporation$10.88-3.12%$2.4B
CLDXCelldex Therapeutics Inc.$28.59-0.83%$2.2B
NTLAIntellia Therapeutics Inc.$9.86+1.65%$1.4B
IDXXIDEXX Laboratories Inc.$700.65-0.51%$55.2B
QDELQuidelOrtho Corporation$10.21-4.93%$700.5M
QUITAchieve Life Sciences Inc. Common Shares$6.06-4.11%$666.8M
NNNNAnbio Biotechnology$3.88+1.57%$558.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier